scispace - formally typeset
Patent

Viral Polymerase Inhibitors

TLDR
An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.
Abstract
An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.

read more

Citations
More filters
Patent

Hepatitis C virus inhibitors

TL;DR: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection as mentioned in this paper, and also disclosed are pharmaceutical compositions containing such compounds and methods to use these compounds in the treatment.
Patent

Modulators of atp-binding cassette transporters

TL;DR: In this article, the present invention relates to modulators of ATP-Binding Cassette transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith.
Patent

Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease

TL;DR: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases and more particularly HCV NS3 proteases as discussed by the authors, and can be used, either alone or in combination, to inhibit viruses, particularly the HCV virus.
Patent

Macrocyclic peptides active against the hepatitis C virus

TL;DR: In this article, the authors defined a pharmaceutically acceptable salt of the HCV NS3 protease, which is useful as an inhibitor of the NS3 protein-protein interaction.
Journal ArticleDOI

Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase

TL;DR: The development of new assays permitted the optimization of enzyme inhibitors leading eventually to molecules with the desired drug-like properties, the most advanced of which are being considered for clinical trials.
References
More filters
Book

Remington : The Science and Practice of Pharmacy

TL;DR: Remington: The Science and Practice of Pharmacy now includes six months free online access to Facts and Comparisons's DrugfactsPlus, the leading source of drug information and pharmacist tools on the Internet.
Journal ArticleDOI

Palladium-catalyzed cross-coupling reactions of organoboron compounds

Norio Miyaura, +1 more
- 01 Nov 1995 - 
TL;DR: In this paper, a cross-coupling reaction is proposed for coupling 1 -Alkenylboron Derivatives: Synthesis of Conjugated Dienes 6.
Journal ArticleDOI

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

TL;DR: A screening window coefficient, called "Z- factor," is defined, which is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements, and therefore is suitable for assay quality assessment.
Journal ArticleDOI

Rapid chromatographic technique for preparative separations with moderate resolution

Abstract: (11) Potassium ferricyanide has previously been used to convert w'c-1,2-dicarboxylate groups to double bonds. See, for example, L. F. Fieser and M. J. Haddadln, J. Am. Chem. Soc., 86, 2392 (1964). The oxidative dldecarboxylation of 1,2-dlcarboxyllc acids is, of course, a well-known process. See Inter alia (a) C. A. Grob, M. Ohta, and A. Weiss, Helv. Chim. Acta, 41, 1911 (1958); and (b) E. N. Cain, R. Vukov, and S. Masamune, J. Chem. Soc. D, 98 (1969).
Journal ArticleDOI

Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line

TL;DR: This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed molecular studies ofHCV and the development of antiviral drugs.
Related Papers (5)